

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
202343Orig1s000

PHARMACOLOGY REVIEW(S)

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH**

PHARMACOLOGY/TOXICOLOGY NDA REVIEW AND EVALUATION

Application Number:	202343
Supporting Document/s:	SDN
Applicant's Letter Date	7 Dec 2010
CDER Stamp Date:	7 Dec 2010
Product:	(MK-0431D)
Indication:	Type 2 diabetes mellitus (T2DM) and hyperlipedemia
Applicant:	Merck
Review Division:	Division of Metabolism and Endocrinology Products (HFD-510)
Reviewer:	Patricia Brundage, Ph.D.
Supervisor/Team Leader:	Todd Bourcier, Ph.D.
Division Director:	Mary Parks, M.D.
Project Manager:	Raymond Chiang

Disclaimer

Except as specifically identified, all data and information discussed below and necessary for approval of NDA 202343 are owned by Merck or are data for which Merck has obtained a written right of reference. Any information or data necessary for approval of NDA 202343 that Merck does not own or have a written right to reference constitutes one of the following: (1) published literature, or (2) a prior FDA finding of safety or effectiveness for a listed drug, as described in the drug's approved labeling. Any data or information described or referenced below from a previously approved application that Merck does not own (or from FDA reviews or summaries of a previously approved application) is for descriptive purposes only and is not relied upon for approval of NDA 202343.

TABLE OF CONTENTS

1	EXECUTIVE SUMMARY	3
1.1	INTRODUCTION	3
1.2	BRIEF DISCUSSION OF NONCLINICAL FINDINGS	3
1.3	RECOMMENDATIONS	4
2	DRUG INFORMATION	5
2.1	DRUG	5
2.2	RELEVANT NDAs AND DMFs	6
2.3	DRUG FORMULATION	6
2.4	COMMENTS ON NOVEL EXCIPIENTS	7
2.5	COMMENTS ON IMPURITIES/DEGRADANTS OF CONCERN	8
2.6	PROPOSED CLINICAL POPULATION AND DOSING REGIMEN	10
2.7	REGULATORY BACKGROUND	10
3	STUDIES SUBMITTED	11
4	PHARMACOLOGY	11
5	PHARMACOKINETICS/ADME/TOXICOKINETICS	12
6	GENERAL TOXICOLOGY	14
	THREE-MONTH ORAL TOXICITY STUDY IN RATS (TT #09-1239)	14
7	GENETIC TOXICOLOGY	25
8	CARCINOGENICITY	26
9	REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY	27
11	INTEGRATED SUMMARY AND SAFETY EVALUATION	29

1 Executive Summary

1.1 Introduction

This is a 505(b)(1) application for the fixed dose combination (FDC) drug product of sitagliptin phosphate and simvastatin (MK-0431D) for the treatment of patients with Type 2 diabetes mellitus (T2DM) and hyperlipidemia. Sitagliptin (Januvia®; Merck; NDA 21-995) was approved by the FDA as an oral anti-hyperglycemic agent, and simvastatin (Zocor®; Merck; NDA 19-766) was approved as an oral anti-hypercholesterolemic agent. Both drug products are approved for chronic use.

This 505(b)(1) application relies primarily on the Agency's findings of safety and efficacy for Januvia® (sitagliptin) and Zocor® (simvastatin). As the sponsor is the primary NDA holder for sitagliptin and simvastatin, all nonclinical information for both components of the FDC were available for review.

The sponsor conducted clinical pharmacology studies to assess the pharmacokinetics of the drug combination as well as possible drug-drug interactions between sitagliptin and simvastatin.

1.2 Brief Discussion of Nonclinical Findings

The nonclinical pharmacology, pharmacokinetics/ADME properties, and toxicity of sitagliptin and simvastatin have been established individually under NDA 21-995 (sitagliptin) and NDA 19-766 (simvastatin).

Due to the concern of possible toxicologic interactions between sitagliptin and simvastatin, especially regarding adverse effects on the skeletal muscle, the sponsor conducted a 3-month co-administration toxicology study in rats to assess the potential toxicity due to co-administration of sitagliptin and simvastatin. There was no mortality or significant adverse clinical effects associated with the co-administration of sitagliptin and simvastatin at exposures greater than 20 times those at the maximum clinical dose of either drug in the FDC. Although there were no adverse muscle or pancreas effects associated with either drug administered alone or in combination, co-administration of sitagliptin and simvastatin did cause an increase in adverse liver effects.

Administration of the simvastatin high dose (60 mg/kg; ~47-114X MHRD; based on AUC) caused an increase in liver weight, hepatocellular hypertrophy, and an increase in ALT levels (~2-3X ↑ compared to controls). Although these effects were not observed in animals administered sitagliptin alone, the co-administration of sitagliptin (180 mg/kg; ~20X MHRD; based on AUC) and simvastatin caused a slightly greater dose-related increase in liver weight (females only) and ALT levels with both the low (30 mg/kg; ~20-66X MHRD; based on AUC) and high (60 mg/kg; ~47-114X MHRD; based on AUC) simvastatin doses suggesting a possible drug-drug interaction between sitagliptin and simvastatin with regards to liver toxicity. Although the sponsor did not establish a NOAEL for the additional increases in liver weight and ALT levels, these adverse liver effects are clinically monitorable. Co-administration of the simvastatin high dose (60 mg/kg; ~47X MHRD; based on AUC) and sitagliptin (180 mg/kg; ~20X MHRD; based on AUC) also caused bile duct hyperplasia. Given that there were no similar findings in animals administered the simvastatin high dose or sitagliptin alone and that bile duct proliferation/hyperplasia was previously observed in rats in studies conducted under NDA 21-995 (sitagliptin) and NDA 19-766 (simvastatin), this finding suggests a potential

drug-drug interaction. However, as a NOEL (30 mg simvastatin/180 mg sitagliptin) was established for this finding at approximately 20 times the human exposure at the MRHD, this is of minimal concern clinically.

Simvastatin treatment was associated with adverse effects in the nonglandular stomach and thyroid. These findings were not markedly affected by the co-administration of sitagliptin. Moreover, they are consistent with those observed in the rat in toxicology studies conducted in support of NDA 19-766 (simvastatin) and are not considered to be clinically relevant.

Information from the genotoxicity, carcinogenicity, and reproductive studies conducted under NDA 21-995 (sitagliptin) and NDA 19-766 (simvastatin) support the chronic administration of MK-0431A XR. Pregnancy category X is recommended for the FDC drug product given that simvastatin is classified in pregnancy category X because lipid lowering drugs offer no benefit during pregnancy when cholesterol and cholesterol derivatives are needed for normal fetal development.

1.3 Recommendations

1.3.1 Approvability

Pharmacology and Toxicology recommends the approval of MK-0431A XR for the proposed indication in adults.

1.3.2 Additional Non Clinical Recommendations

No additional nonclinical studies are required.

1.3.3 Labeling

The nonclinical labeling information for the FDC drug product of sitagliptin and simvastatin (MK-0431D) is similar to the language used in the labels for which the sponsor is the primary NDA holder for both drug products. The safety margin for simvastatin regarding the teratogenicity studies (under Section 8.1) will need to be corrected to account for the maximum simvastatin dose of 40 mg/day; change to the proposed label is underlined. Additionally, the paragraph discussing the results of the 3-month rat co-administration study should be deleted as it does not contain nonclinical data pertinent to the safe/effective use of the drug.

8.1 Pregnancy

Simvastatin

Simvastatin was not teratogenic in rats or rabbits at doses (25, 10 mg/kg/day, respectively) that resulted in 6 times the human exposure based on mg/m² surface area. However, in studies with another structurally-related statin, skeletal malformations were observed in rats and mice.

13.2 Animal Toxicology and/or Pharmacology

(b) (4)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.